

Docket Number: 037003-0276603

PATENT APPLICATION

Client Reference: 1995-30-0233D2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of

ANDERSON et al.

Group Art Unit: 1644

Application No.: 09/758,173

Examiner: Phillip Gambel

Filed: January 12, 2001

Confirmation No.:

For: HUMAN B7.1 SPECIFIC PRIMATIZED ANTIBODIES AND TRANSFECTOMAS
EXPRESSING SAID ANTIBODIES

INFORMATION DISCLOSURE STATEMENT


Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed with a Request for Continued Examination. No certification or fee is required.

Respectfully Submitted,



Thomas A. Cawley, Jr., Ph.D,
Registration Number 40944

Date: November 26, 2003
PILLSBURY WINTHROP LLP
Telephone: (703) 905-2000
Facsimile: (703) 905-2500
P.O. Box 10500
McLean, VA 22102



30417824v1

Nov-26-03 14:43 From-PILLSBURY WINTHROP
 FORM PTO-1449 (modified)
 To: U.S. Department of Commerce
 (PW FORM PAT-1449)
 Patent and Trademark Office

703-905-2500

T-845 P.012/076 F-461

Atty. Dkt. No.	M#	Client Ref.
	037003-0276603	1995-30-0233D2

**INFORMATION DISCLOSURE STATEMENT
 BY APPLICANT**

Applicant:	ANDERSON et al.
Appl. No.:	09/758,173
Filing Date:	January 12, 2001
Examiner:	Gambel, P. Group Art Unit: 1644

Date: November 26, 2003 Page 1 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					
	CR					
	DR					
	ER					
	FR					

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name		Abstract		Readily Available	
						Enclosed	No	Enclose	No
	GR								
	HR								
	IR								
	JR								
	KR								
	LR								
	MR								

OTHER (Including in this order Author, Title, Periodical Name, Volume, Pertinent Pages, Date)

NR	Kuchroo et al., "B7-1 and B7-2 Costimulatory Molecules Activate Differentially the Th1/Th2 Developmental Pathways: Application to Autoimmune Disease Therapy," <i>Cell</i> , 80:707-718 (1995).
OR	Lenschow et al., "Inhibition of Transplant Rejection Following Treatment with Anti-B7-2 and Anti-B7-1 Antibodies," <i>Transplantation</i> 60:1171-1178 (1995).
PR	Lenschow et al., "Differential Effects of Anti-B7-1 and Anti-B7-2 Monoclonal Antibody Treatment on the Development of Diabetes in the Nonobese Diabetic Mouse," <i>J. Exp. Med.</i> 181:1145-1155 (1995).
QR	Nakajima et al., "Preferential dependence of autoantibody production in murine lupus on CD86 co-stimulatory molecule," <i>Euro. J. Immunol.</i> 25(11):3060-3069 (Nov. 1995).
RR	Van Gool et al., "Synergy Between Cyclosporin A and a Monoclonal Antibody to B7 in Blocking Alloantigen-Induced T-Cell Activation," <i>Blood</i> , 83:176-183 (1994).
SR	Wettendorf et al., "Generation of Humanized Fab Fragments of B7-24 mAb, An Antibody with Potential Use in the Prevention of Graft Rejection and Development of Graft-Versus-Host Disease," <i>Med. Fac. Landbouww. Univ. Gent.</i> 60(4):2057-2063, Published 27 September, 1995 - not early enough to be valid prior art.
TR	Supplementary European Search Report for Application No. EP 97913955, dated January 31, 2001.
UR	EPO Communication in Application No. EP 96922439, dated May 28, 2002.
VR	

Examiner	Date Considered:
----------	------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.